Consideringthe important role of CSF biomarkers in early detectionof AD, we aimed to identify blood-circulating miRNAs associated withthe levels of the CSF biomarkers Aβ1–42, T-tau, and P-tau181.To achieve this, we employed a linear mixed model that consideredage, gender, education, and medication—factors that might affectcognitive function in AD.36−38 We included plasma- and serum-circulatingmiRNAs by an unbiased approach of next-generation sequencing from112 participants including AD, MCI due to AD, and not age-matchedbut cognitively healthy control subjects. The gene discussed is MAPT; the disease is Alzheimer disease.